Clinical trial · no report yet · Phase 1
NCT06034002
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- NCT06034002 ↗
- Recruiting
- Incyte Corporation
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- INCA033989; Ruxolitinib
- Arms
- Part 1a Dose Escalation Cohort Disease Group A - with MF · Experimental
- Part 1a Dose Escalation Cohort Disease Group A - with ET · Experimental
- Part 1a: Dose Escalation Cohort Disease Group B - with TGB-MF SubOpt R · Experimental
- Part 1b: Dose Expansion - with MF · Experimental
- Part 1b: Dose Expansion - with TGB-MF SubOpt R · Experimental
- Part 1b: Dose Expansion - with ET · Experimental
- Part 1c: Dose Expansion · Experimental
- Enrollment
- 290 (estimated)
- Primary outcomes
- Number of participants with Dose Limiting Toxicities (DLTs)
- Number of participants with Treatment-emergent Adverse Events (TEAEs)
- Sponsor
- Incyte Corporation
- Start
- Dec 4, 2023
- Primary completion
- Oct 29, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06034002 · updated Apr 17, 2026